Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
July 18 2024 - 7:30PM
Business Wire
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”,
Nasdaq: ARCT), a global messenger RNA medicines company focused on
the development of infectious disease vaccines and medicines to
treat unmet medical needs within liver and respiratory rare
diseases, today announced that it will release its financial
results for the quarter ended June 30, 2024 after the market close
on Monday, August 5 and will also host a conference call and
webcast at 4:30 pm Eastern Time on August 5, 2024.
Arcturus Therapeutics Second Quarter 2024 Earnings Conference
Call
- Monday, August 5, 2024 @ 4:30 p.m. ET
- Domestic: 1-877-407-0784
- International: 1-201-689-8560
- Conference ID: 13747924
- Webcast: Link
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus
Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA
medicines and vaccines company with enabling technologies: (i)
LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology
(sa-mRNA) and (iii) mRNA drug substance along with drug product
manufacturing expertise. Arcturus developed Kostaive®, the first
self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world
to be approved. Arcturus has an ongoing global collaboration for
innovative mRNA vaccines with CSL Seqirus, and a joint venture in
Japan, ARCALIS, focused on the manufacture of mRNA vaccines and
therapeutics. Arcturus’ pipeline includes RNA therapeutic
candidates to potentially treat ornithine transcarbamylase
deficiency and cystic fibrosis, along with its partnered mRNA
vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’
versatile RNA therapeutics platforms can be applied toward multiple
types of nucleic acid medicines including messenger RNA, small
interfering RNA, circular RNA, antisense RNA, self-amplifying RNA,
DNA, and gene editing therapeutics. Arcturus’ technologies are
covered by its extensive patent portfolio (over 400 patents and
patent applications in the U.S., Europe, Japan, China, and other
countries). For more information, visit www.ArcturusRx.com. In
addition, please connect with us on Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240718093749/en/
IR and Media Contacts Arcturus Therapeutics Neda
Safarzadeh VP, Head of IR/PR/Marketing IR@arcturusrx.com
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Aug 2023 to Aug 2024